Dermatology News

Bimekizumab remains effective after 52 weeks in patients with psoriatic arthritis, with no new safety concerns, according to data published in Annals of the Rheumatic Diseases.

The FDA has approved a supplemental biologics licensing application from Bristol Myers Squibb expanding the indication of abatacept to include children aged 2 years and older with psoriatic arthritis, according to a company press release.

Mounting evidence suggests that herpes simplex virus 1 may be associated with an increased risk for Alzheimer’s disease and dementia, according to a systematic review of published studies.

Vibrio cases and deaths in Florida spiked last year after Hurricane Ian, lending credence to concerns that larger, longer, warmer tropical storms may increase the risk for viral infections, according to a study.

Patients across health care specialties have in recent years come to expect some form of individually tailored care — or precision medicine — as part of their disease management.

A higher proportion of patients are dying from nonmelanoma skin cancer globally than melanoma, according to a press release from the European Academy of Dermatology and Venerology.

In this edition, FDA issues complete response letter for relabotulinumtoxinA; mucocutaneous manifestations may signal COVID-induced inflammatory disease in children and more.

The FDA has denied a biologics license application from Alvotech for its biosimilar to ustekinumab, citing “certain deficiencies” at the company’s facility in Reykjavik, Iceland, according to the manufacturer.

Each year, WHO marks World Mental Health Day on Oct. 10 in an effort to raise awareness of mental health issues around the world and mobilize efforts to support mental health.

The FDA has approved a supplemental new drug application for Zoryve expanding its indication to include treatment of psoriasis in pediatric patients, Arcutis Biotherapeutics announced in a press release.